Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells
Rui Zhang, Na Chen, Mengnan Li, Qingxi Liu, Mingfeng Zhao · 2026
Read Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells by Rui Zhang, Na Chen, Mengnan Li, Qingxi Liu, Mingfeng Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675449.txt.
Description
Rui Zhang and co-authors engineer safer cell therapy for acute myeloid leukemia in a 2026 study. CAR-T cells aimed at the CLL1 marker can kill this blood cancer, but CLL1 also sits on healthy neutrophils, so treatment can wipe out those key defenders. The team built a two-key lock to spare them.
Their synthetic Notch design fires only when a T cell meets both CD123 and CLL1, a pairing found on leukemia blasts. In dish tests the gated cells killed blasts harder and spared neutrophils more. They also showed fewer signs of exhaustion and kept a younger profile. In mouse models they expanded better and lasted longer. Dual gating may widen the safe use of CAR-T in this leukemia.
Catalog record
| CREATOR | Rui Zhang, Na Chen, Mengnan Li, Qingxi Liu, Mingfeng Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |